Cody Pietras
Director 3DownloadHi-Res Photo
Cards
Additional Titles
Executive Director, Yale Cardiovascular Research Group
Contact Info
About
Titles
Director 3
Executive Director, Yale Cardiovascular Research Group
Biography
Mr. Pietras is a medical editor and clinical trial design specialist with more than 10 years of experience in the field of cardiovascular clinical research.
Appointments
Departments & Organizations
- Internal Medicine
- Yale Cardiovascular Clinical Research
- Yale Cardiovascular Research Group
- YCRG Operations
Education & Training
- BA
- Dartmouth College, Psychology & Behavioral Neuroscience (2003)
Research
Overview
Medical Subject Headings (MeSH)
Cardiovascular Diseases; Cardiovascular Surgical Procedures; Catheterization; Drug Therapy; Thrombolytic Therapy
- View Lab Website
Yale Cardiovascular Clinical Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Cody Pietras's published research.
Publications Timeline
A big-picture view of Cody Pietras's research output by year.
Research Interests
Research topics Cody Pietras is interested in exploring.
Alexandra Lansky, MD, FACC, FAHA, FESC
Helen Parise, ScD
Daniela Tirziu, PhD
John K Forrest, MD, FACC, FSCAI
Louise Gambone
Alexander Thomas, MD
36Publications
807Citations
Cardiovascular Surgical Procedures
Cardiovascular Diseases
Catheterization
Drug Therapy
Publications
2024
Determining the Cause of Coronary Vasomotor Disorders in Patients With Ischemia and Nonobstructive Coronary Arteries: Design and Rationale of the DISCOVER INOCA Prospective, Multicenter Registry
Shah S, Tremmel J, Henry T, Smilowitz N, Prasad M, Kobayashi Y, Henry G, Samady H, Samuels B, Lerman A, Moses J, Pietras C, Zhang Z, Tirziu D, Parise H, Cristea E, Chamié D, Grubman D, Henrici K, Matmusaeva E, Latif N, Cigarroa N, Lansky A. Determining the Cause of Coronary Vasomotor Disorders in Patients With Ischemia and Nonobstructive Coronary Arteries: Design and Rationale of the DISCOVER INOCA Prospective, Multicenter Registry. Journal Of The Society For Cardiovascular Angiography & Interventions 2024, 3: 102046. PMID: 39132594, PMCID: PMC11308755, DOI: 10.1016/j.jscai.2024.102046.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCoronary function testingObstructive coronary artery diseaseCoronary artery diseaseNonobstructive coronary arteriesLong-term outcomesFollow-upVasomotor disordersEnd pointsComposite of cardiovascular deathCoronary arteryLong-term follow-upCoronary microvascular dysfunctionDiagnostic coronary angiographyCardiovascular adverse eventsAdverse cardiovascular eventsCoronary vasomotor disordersOptical coherence tomographySymptomatic myocardial bridgingShort-term end pointsAtherosclerotic plaque burdenIschemic heart diseaseLong-term end pointsINOCA patientsAcetylcholine provocationPatient-reported outcome measuresPREDICTORS AND CONSEQUENCES OF BRAIN INJURY VOLUME BY DIFFUSION-WEIGHTED MRI FOLLOWING TAVR
Grubman D, Dwyer M, Lansky A, Zivadinov R, Pietras C, Nazif T, Moses J, Shah T, Gambone L, Parise H, Messe S. PREDICTORS AND CONSEQUENCES OF BRAIN INJURY VOLUME BY DIFFUSION-WEIGHTED MRI FOLLOWING TAVR. Journal Of The American College Of Cardiology 2024, 83: 970. DOI: 10.1016/s0735-1097(24)02960-7.Peer-Reviewed Original Research800.09 Surgical Risk Does Not Predict Ischemic Stroke or Acute Infarction After TAVR: Results of a Patient-Level Pooled Analysis
Grubman D, Lansky A, Dwyer M, Zivadinov R, Pietras C, Nazif T, Moses J, Shah T, Gambone L, Leon M, Forrest J, Vora A, Parise H, Messé S. 800.09 Surgical Risk Does Not Predict Ischemic Stroke or Acute Infarction After TAVR: Results of a Patient-Level Pooled Analysis. JACC Cardiovascular Interventions 2024, 17: s67-s68. DOI: 10.1016/j.jcin.2024.01.234.Peer-Reviewed Original Research
2023
Chocolate Touch Versus Lutonix Drug-Coated Balloon for Femoropopliteal Lesions in Diabetes: The Chocolate Touch Study.
Böhme T, Zeller T, Shishehbor M, Werner M, Brodmann M, Parise H, Holden A, Lichtenberg M, Parikh S, Kashyap V, Pietras C, Tirziu D, Beschorner U, Krishnan P, Niazi K, Wali A, Lansky A. Chocolate Touch Versus Lutonix Drug-Coated Balloon for Femoropopliteal Lesions in Diabetes: The Chocolate Touch Study. Journal Of Endovascular Therapy 2023, 15266028231179589. PMID: 37314243, DOI: 10.1177/15266028231179589.Peer-Reviewed Original ResearchCitationsConceptsLutonix drug-coated balloonDrug-coated balloonsPrimary safety endpointDM statusFemoropopliteal diseaseDiabetes mellitusSafety endpointFemoropopliteal lesionsSimilar safetyHigh-risk patient populationFemoropopliteal artery lesionsIschemic rest painNon-DM patientsSymptomatic femoropopliteal lesionsPrimary efficacy endpointMajor adverse eventsTherapy of choiceDrug-Coated BalloonMajor amputationRest painEfficacy endpointPrimary patencyAdverse eventsArtery lesionsDiabetes statusCerebral Embolic Risk in Coronary and Structural Heart Interventions: Clinical Evidence
Tirziu D, Huang H, Parise H, Pietras C, Moses J, Messé S, Lansky A. Cerebral Embolic Risk in Coronary and Structural Heart Interventions: Clinical Evidence. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 100631. PMID: 39130705, PMCID: PMC11307836, DOI: 10.1016/j.jscai.2023.100631.Peer-Reviewed Original ResearchAltmetricConceptsStructural heart interventionsHeart interventionsCardiac proceduresBrain injuryLong-term neurocognitive sequelaeTranscatheter aortic valve replacement (TAVR) proceduresAortic valve replacement proceduresCerebral embolic riskIatrogenic brain injuryIschemic brain injuryRisk of thromboembolismCoronary artery diseaseEmbolic protection devicesNumber of patientsValve replacement proceduresPercutaneous transcatheter interventionsLikelihood of disabilitySymptomatic strokeCerebral embolismCerebral embolizationEmbolic riskAcute strokeNeurologic injuryArtery diseaseIschemic infarctionThe Supreme Biodegradable Polymer DES in Acute and Chronic Coronary Syndromes: A PIONEER III Substudy
Hussain Y, Saito S, Curtis M, Kereiakes D, Baumbach A, Zidar J, McLaurin B, Dib N, Smits P, Díaz V, Cequier Á, Hofma S, Pietras C, Dressler O, Issever M, Windecker S, Leon M, Lansky A, Investigators I. The Supreme Biodegradable Polymer DES in Acute and Chronic Coronary Syndromes: A PIONEER III Substudy. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 100629. PMID: 39130696, PMCID: PMC11307614, DOI: 10.1016/j.jscai.2023.100629.Peer-Reviewed Original ResearchAltmetricConceptsTarget lesion failureAcute coronary syndromeChronic coronary syndromePrimary end pointCoronary syndromeDP-EESClinical presentationMajor adverse cardiac eventsEnd pointAdverse cardiac eventsBiodegradable polymer DESPrevious revascularizationLesion failureCardiac eventsCurrent smokersIII trialsLess diabetesCCS groupStent thrombosisPatientsRelative safetyDurable polymerSyndromeMonthsInteraction P
2022
Geographic Variations on the Safety and Efficacy of the Supreme Biodegradable Polymer DES: Results From PIONEER III
Garot P, Leon M, Saito S, Baumbach A, Kereiakes D, Windecker S, Pietras C, Dressler O, Issever M, Curtis M, Bertolet B, Zidar J, Smits P, Diaz V, McLaurin B, Cequier A, Hofma S, Dib N, Namiki A, Takahashi A, Kakuta T, Hirohata A, Lansky A. Geographic Variations on the Safety and Efficacy of the Supreme Biodegradable Polymer DES: Results From PIONEER III. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 2: 100515. PMID: 39132534, PMCID: PMC11308104, DOI: 10.1016/j.jscai.2022.100515.Peer-Reviewed Original ResearchAltmetricConceptsDrug-eluting stentsDurable polymer everolimus-eluting stentsEverolimus-eluting stentsIII trialsLesion failureClinical outcomesMyocardial infarctionMajor adverse cardiac eventsVessel-related myocardial infarctionBiodegradable polymer drug-eluting stentsAdverse cardiac eventsOutcomes of patientsTarget lesion failureTarget lesion revascularizationLesion revascularizationCardiac eventsPatient characteristicsCardiac deathDES groupProcedural successStent thrombosisSubgroup analysisPatient outcomesNonsignificant trendEnrollment locationImpella Versus Intra-Aortic Balloon Pump for High-Risk PCI: A Propensity-Adjusted Large-Scale Claims Dataset Analysis
Lansky AJ, Tirziu D, Moses JW, Pietras C, Ohman EM, O'Neill WW, Ekono MM, Grines CL, Parise H. Impella Versus Intra-Aortic Balloon Pump for High-Risk PCI: A Propensity-Adjusted Large-Scale Claims Dataset Analysis. The American Journal Of Cardiology 2022, 185: 29-36. PMID: 36210212, DOI: 10.1016/j.amjcard.2022.08.032.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHigh-risk percutaneous coronary interventionIntra-aortic balloon pumpPercutaneous coronary interventionAcute kidney injuryCardiogenic shockMyocardial infarctionIABP supportKidney injuryBalloon pumpImproved survivalPropensity adjustmentAcute ST-elevation myocardial infarctionST-elevation myocardial infarctionIndex hospitalization lengthLess myocardial infarctionPremier Healthcare DatabaseHospital myocardial infarctionPropensity-adjusted analysisMechanical circulatory supportMechanical support devicesImpella useHospital survivalIndex hospitalizationCoronary interventionReal-world practiceRandomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study)
Shishehbor MH, Zeller T, Werner M, Brodmann M, Parise H, Holden A, Lichtenberg M, Parikh SA, Kashyap VS, Pietras C, Tirziu D, Ardakani S, Beschorner U, Krishnan P, Niazi KA, Wali AU, Lansky AJ. Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study). Circulation 2022, 145: 1645-1654. PMID: 35377157, DOI: 10.1161/circulationaha.122.059646.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsLutonix drug-coated balloonDrug-coated balloonsEnd pointPrimary efficacy end pointPrimary safety end pointIndependent clinical events committeeIschemic rest painPrimary efficacy rateEfficacy end pointPrimary end pointSafety end pointClinical events committeeMajor adverse eventsRate of restenosisDrug-Coated BalloonNoninferiority end pointSafety event rateAverage lesion lengthMajor amputationPopliteal diseaseRest painBailout stentingEfficacy ratePrimary patencyAdverse eventsCLINICAL PREDICTORS OF EMBOLIC BURDEN AFTER TAVR: AN ANALYSIS OF THE SAFEPASS 2 CLINICAL STUDY
Lansky A, White J, Stewart J, Blake J, Smyth D, Pasupati S, Nair R, Parise H, Pietras C, Webster M, Kawakami R, Virmani R, Leipsic J. CLINICAL PREDICTORS OF EMBOLIC BURDEN AFTER TAVR: AN ANALYSIS OF THE SAFEPASS 2 CLINICAL STUDY. Journal Of The American College Of Cardiology 2022, 79: 628. DOI: 10.1016/s0735-1097(22)01619-9.Peer-Reviewed Original Research
Links & Media
News
- April 01, 2024
Yale Faculty Present Groundbreaking Clinical Research at the 2024 American College of Cardiology Scientific Sessions
- January 26, 2022
American College of Cardiology 71st Annual Scientific Session & Expo sessions announced
- August 05, 2021
Cody Pietras Appointed Executive Director of the Yale Cardiovascular Research Group
- April 28, 2021
59 Staff in Department Celebrate Service Milestones